AI Terminal
4SC AG
Report Publication Announcement • May 6, 2016
5_rns_2016-05-06_4272708b-8e60-4cf7-9a73-a4cd4cbc0531.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 6 May 2016 09:38
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016 interim communication
DGAP-News: 4SC AG / Key word(s): Quarterly / Interim Statement/Quarter Results
2016-05-06 / 09:38
The issuer is solely responsible for the content of this announcement.
4SC AG: Conference call to be hosted on 12 May 2016 to present Q1 2016 interim communication
Planegg-Martinsried, Germany, 6 May 2016 – 4SC AG (4SC, FSE Prime Standard: VSC) will publish its Q1 2016 interim communication on 12 May 2016. On this day, the Management Board of 4SC AG will host a conference call at 4 pm CEDT (10 am EDT) to inform about important developments in the reporting period and beyond.
Investors, financial analysts, and journalists interested in participating in the conference call can access via the following telephone numbers:
| Date: | 12 May 2016 |
| Time: | 4 pm CEDT (10 am EDT) |
| Dial-in numbers: | +49 89 1214 00699 (Germany) |
| +44 20 3427 1912 (UK) | |
| +1 212 444 0412 (USA) | |
| +49 89 1214 00699 (all other countries) | |
| Conference ID: | 3705834 |
A presentation document supporting the conference call will be available on 12 May 2016, on the webpage www.4sc.com in section “Investors & Media” / “Events & Presentations” / “Conference Calls & Webcasts”. After the event, a replay can be accessed from there as well.
– Press release ends –
Further information
About 4SC
4SC ( www.4cs.com ) is a biotechnology company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 67 employees at 31 December 2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Forward-looking information
This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.
More information about 4SC
4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, [email protected], +49 89 700763-73
Dr. Anna Niedl, [email protected], +49 89 700763-66
MC Services
Katja Arnold, [email protected], +49 89 210228-40
2016-05-06 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | 4SC AG |
| Am Klopferspitz 19a | |
| 82152 Planegg-Martinsried | |
| Germany | |
| Phone: | +49 (0)89 7007 63-0 |
| Fax: | +49 (0)89 7007 63-29 |
| E-mail: | [email protected] |
| Internet: | www.4sc.com |
| ISIN: | DE000A14KL72 |
| WKN: | A14KL7 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |